[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356206-105":59,"doc-detail-356206-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","risk-and-benefit-for-targeted-therapy-agents-in-paediatric-phase-i-trials-in-oncology-a-systematic-review-and-metaanalysis-protocol","Risk and benefit for targeted therapy agents in paediatric phase I trials in oncology - a systematic review and metaanalysis protocol","","Paediatric phase I oncology trials set safe dosing and provide early efficacy signals for investigational anti-cancer agents in children. This systematic review protocol aims to quantify the risk–benefit ratio for targeted therapy agents in paediatric Phase I oncology trials. Searches of Embase and PubMed will cover 2 March 2015 to 30 June 2026. Co-primary outcomes include drug-related grade 3–5 adverse events and objective response rate, with random-effects meta-analysis where feasible.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-and-benefit-for-targeted-therapy-agents-in-paediatric-phase-i-trials-in-oncology-a-systematic-review-and-metaanalysis-protocol/356206/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-and-benefit-for-targeted-therapy-agents-in-paediatric-phase-i-trials-in-oncology-a-systematic-review-and-metaanalysis-protocol/356206.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of this systematic review protocol?","Question",{"text":113,"@type":114},"To identify the risk and benefit ratio for targeted therapy agents in paediatric Phase I oncology trials.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which trials and participants will be included?",{"text":118,"@type":114},"Dose-escalation paediatric Phase I cancer trials enrolling participants under 21 years with solid or haematological malignancies that test targeted therapy agents.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the co-primary outcomes?",{"text":122,"@type":114},"Risk is measured as the proportion experiencing drug-related adverse events of grade 3, 4, or 5, and benefit is measured as objective response rate.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356206,1790438592,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Open access Protocol  \n Risk and benefit for targeted therapy  \nagents in paediatric phase I trials in oncology: a systematic review and metaanalysis protocol  \nJoanna Ostrowska  , Karolina Strzebonska  , Marcin Waligora   \nTo cite: Ostrowska J, Strzebonska K, Waligora M.  \nRisk and benefit for targeted therapy agents in paediatric phase I trials in oncology: a systematic review and metaanalysis protocol. BMJ Open 2026;16:e123756 . doi:10 . 1136/ bmjopen-2026-123756  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2026-123756](bmjopen-2026-123756)) .  \nReceived 05 June 2026 Accepted 20 August 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group.  \nREMEDY, Research Ethics in Medicine Study Group, Department of Bioethics and Health Psychology, Jagiellonian University Medical College, Krakow, Poland  \nCorrespondence to  \nDr Marcin Waligora; [m.waligora@uj.edu.pl](m.waligora@uj.edu.pl)  \nABSTRACT  \nIntroduction Paediatric phase I oncology trials establish safe dosing and provide preliminary efficacy data for investigational anti-cancer agents in children. The aim of the proposed systematic review is to identify the risk and benefit ratio for targeted therapy agents in paediatric Phase I trials in oncology.  \nMethods and analysis We will search Embase and PubMed for paediatric Phase I cancer trials published from 2 March 2015 to 30 June 2026. Eligible studies are dose-escalation trials enrolling participants under 21 years with solid or haematological malignancies, testing targeted therapy agents. We will measure two co-primary outcomes: (1) risk—proportion of participants experiencing drug-related adverse events of grade 3, 4 or 5; and (2) benefit—objective response rate. Where data permit, proportions will be pooled using random-effects meta-analysis.  \nEthics and dissemination This study will use publicly available data; therefore, ethics committee approval isnot required. Results from the systematic review will be published in a peer-reviewed journal and presented at relevant conferences.  \nPROSPERO registration number CRD420261408673 .  \nINTRODUCTION  \nPaediatric phase I oncology trials establish the maximum tolerated dose (MTD) orthe recommended Phase II dose (RP2D), characterise pharmacokinetic and pharmacodynamic profiles, and provide preliminary evidence of anti-tumour activity. They raise several distinct ethical challenges. First, minors under 16 cannot give consent for participation; proxy consent and ageappropriate child assent are required, which may compromise participants’ developing autonomy.1 2 Second, participants typically have advanced or refractory disease and have exhausted standard therapeutic options, which raises concerns about therapeutic misunderstanding.3 4 Third, the risk–benefit balance is inherently more uncertain than in later-phase studies: participants are exposed to investigational agents of uncertain toxicity  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ The planned systematic review was prospectively registered in PROSPERO, and this protocol adheres to PRISMA-P guidelines.  \n⇒ The systematic review will be conducted and reported in accordance with PRISMA 2020 guidelines.  \n⇒ Study selection and data extraction will be performed independently by two researchers, with arbitration by a third reviewer when required.  \n⇒ High between-study heterogeneity is anticipated and will be addressed through pre-specified subgroup and sensitivity analyses.  \n⇒ Risk of bias assessment will not be performed, as phase I clinical trials are primarily designed to evaluate safety and dose rather than comparative effectiveness.  \nin the pursuit of dose-finding rather than direct therapeutic benefit.5 Fourth, the rarity of paediatric cancers constrains sample sizesand limits st","cbCain6WYOM80OMM","https://ap.wps.com/l/cbCain6WYOM80OMM","pdf",306823,"English","# Introduction\n## Ethical challenges in paediatric Phase I oncology trials\n# Methods and analysis\n## Study search and eligibility\n## Co-primary outcomes and meta-analysis approach\n# Ethics and dissemination\n## Use of publicly available data and publication plans\n# Strengths and limitations of the study\n## Registration, reporting, and data handling","[{\"question\":\"What is the main goal of this systematic review protocol?\",\"answer\":\"To identify the risk and benefit ratio for targeted therapy agents in paediatric Phase I oncology trials.\"},{\"question\":\"Which trials and participants will be included?\",\"answer\":\"Dose-escalation paediatric Phase I cancer trials enrolling participants under 21 years with solid or haematological malignancies that test targeted therapy agents.\"},{\"question\":\"What are the co-primary outcomes?\",\"answer\":\"Risk is measured as the proportion experiencing drug-related adverse events of grade 3, 4, or 5, and benefit is measured as objective response rate.\"}]","Risk and benefit for targeted therapy agents in paediatric phase I trials in oncology - a systematic review and metaanalysis protocol | PDF",1790124056,13,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3cc615f868457cfc03fd75d464035de.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/808c7a20f782d11d8bff6737cd0a1efe.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94e5b239b68e46f3d54a021fbe095a8c.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85456219010c2c5c97494aac8d8fc0f0.webp",980,1306]